A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 313-318

  Sirotnak, F M ^a   DeGraw, J I ^b   Colwell, W T ^b   Piper, J R ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SRI INTERNATIONAL   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

10 Propargyl 10 deazaaminopterin; Cytotoxicity; Efficacy; Human tumors

Indexed keywords

10 DEAZAAMINOPTERIN; 10 PROPARGYL 10 DEAZAAMINOPTERIN; AMINOPTERIN; DIHYDROFOLATE REDUCTASE; EDATREXATE; FOLIC ACID DERIVATIVE; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

AMINOPTERIN; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HUMANS; LUNG NEOPLASMS; METHOTREXATE; MICE; MICE, NUDE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE; TUMOR CELLS, CULTURED;

EID: 0031851925     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050823     Document Type: Article

References (19)

1. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ (1984) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12: 18-25
2. Sirotnak FM, DeGraw JI, Schmid FA, Goutas LL. Moccio DM (1984) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12: 26-30
3. Schmid FA, Sirotnak FM, Otter GM, DeGraw JI (1985) New folate analogs of the 10-deaza-aminopterin series. Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumors xenografts in nude mice. Cancer Treat Rep 69: 551-553
4. Sirotnak FM, Schmid FA, Samuels LL, DeGraw JI (1987) 10-ethyl-10-deazaaminopterin: Structural design and biochemical, pharmacologic and antitumor properties. NCI Monogr. 5: 127-131
5. Sirotnak FM, Chello PL, Brockman RW (1979) Potential for exploitation of transport systems in anticancer drug design. Methods Cancer Res. 16, 381-447
6. Sirotnak FM (1983) Concepts in new folate analog design. In: Cheng Y-C, Goz B, Minkoff M (eds.) Development of target-oriented anticancer drugs. Vol. 28 Progress in cancer research and therapy. Raven Pres, New York, pp 77-96
7. Sirotnak FM, DeGraw JI (1984) Selective antitumor action of folate analogs. In: Sirotnak FM, Burchall JJ, Ensminger WD, Montgomery JA (eds) Folate antagonists and therapeutic agents, vol 1. Academic Press, New York, pp 173-207
8. Shum KY, Kris MG, Gralla RJ, Patanovich LM, Marks LD, Hellan RT (1988) Phase II study of 10-ethyl-10-deazaaminopterin in patients with stage IIIb and IV nonsmall cell lung cancer. J Clin Oncol 6: 446-450
9. Vandenberg TA, Pritchard KI, Eisenhauer EA, Trudeau ME, Norris BD, Lopez P, Verma SS, Buchman RA, Muddal A (1992) Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study. J Clin Oncol 11, 1241-1244
10. Casper ES, Christman KL, Schwartz GK, Johnson B, Brennan MF, Bertino JR (1993) Edatrexate in patients with soft tissue sarcoma. Cancer 72: 766-770
11. Rumberger BG, Barrucco JR, Sirotnak FM (1990) Differing specificities for 4-amino folate analogs of folylpolyglutamate synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res. 50: 4639-4643
12. Sirotnak, FM (1980) Correlates of folate analog transport, pharmacokinetics and selective antitumor action. Pharmacol. Ther 8: 71-103
13. Goldman ID, Matherly LH (1986) Cellular pharmacology of methotrexate. In: Goldman ID, (ed) Membrane transport of antineoplastic agents. International encyclopedia of pharmacology therapy, sect 118. Pergamon Press, New York, pp 283-302
14. Samuels LL, Moccio DM, Sirotnak FM (1985) Similar differential for polyglutamylation and cytotoxicity among various folate analogs and tumor cells in vivo. Cancer Res 45: 1488-1495
15. DeGraw JI, Colwell WT, Piper JR, Sirotnak FM (1992) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36: 2228-231
16. Chou T-C, Otter GM, Sirotnak FM (1996) Schedule-dependent synergism of taxol and taxoterc with edatrexate against human breast cancer cells in vivo. Cancer Chemother Pharmacol. 37: 222-228
17. Zar JH (1984) Biostatistical analysis, 2nd edn. Prentice Hall, Englewood Clifls, pp 145-146
18. Chabner BA (1982) Methotrexate. In: Chabner BA (ed) Pharmacologic principles of cancer treatment. WB Saunders, Philadelphia, pp. 229-258
19. Piper JR, McCaleb GS, Montgomery JA, Kisliuk RL, Goumont Y, Sirotnak FM (1992) 10-propargylaaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism. J Med Chem 25: 877-880